AnaptysBio Announces Biopharma Spin-Off and Strong 2025 Financials: Key Investor Insights

Key Highlights

• Strategic Spin-Off: AnaptysBio plans to separate its biopharma operations into a new publicly traded company, First Tracks Biotherapeutics (Nasdaq: TRAX), as early as late April 2026, but no later than Q2 2026.
• Strong Jemperli Performance: GSK’s Jemperli (dostarlimab-gxly), for which AnaptysBio receives royalties, achieved >13% quarter-over-quarter growth, with Q4 2025 sales of \$343 million and a \$1.4 billion annualized run rate. This triggers significant milestones and future royalty potential for AnaptysBio.
• Financials: End-2025 cash and investments stand at \$311.6 million despite share repurchases and R&D spend. Q4 2025 net income was \$49.6 million, and the company repurchased 11.2% of its shares outstanding during 2025.
• Clinical Pipeline Progress: Multiple pipeline assets are advancing, including ANB033 (Phase 1b for celiac disease and eosinophilic esophagitis), rosnilimab (pathogenic T cell depleter for rheumatoid arthritis), and ANB101 (BDCA2 modulator).
• Vanda Collaboration: Imsidolimab’s BLA for generalized pustular psoriasis (GPP) was accepted by the FDA, with a target action date of December 12, 2026.
• Debt Repayment: The company anticipates full paydown of its \$600 million non-recourse debt monetization by the end of Q2 2027 due to royalty streams and milestones.

Detailed Article

San Diego, March 3, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company, has announced a transformative restructuring and robust financial and pipeline updates that could have significant implications for investors.

Business Separation: Unlocking Value for Investors

The company has confirmed plans to spin off its wholly owned biopharma portfolio into a new public entity, First Tracks Biotherapeutics (Nasdaq: TRAX), with the process on track for completion in Q2 2026 and possibly as soon as late April. This move is designed to unlock and amplify value by creating two distinct investment opportunities:

• AnaptysBio (Nasdaq: ANAB): Will retain substantial royalty assets and focus on financial collaborations, primarily from Jemperli (with GSK) and imsidolimab (with Vanda Pharmaceuticals).
• First Tracks Biotherapeutics (Nasdaq: TRAX): Will focus on advancing and potentially commercializing innovative immunology therapeutics, including ANB033, rosnilimab, and ANB101.

The royalty management company will initially retain the AnaptysBio name, with Daniel Faga expected to serve as CEO. First Tracks Biotherapeutics’ initial board will include key current AnaptysBio directors, ensuring continuity and experience.

Jemperli Royalties: A Potential Game-Changer

GSK’s commercial performance with Jemperli, a PD-1 antagonist discovered by AnaptysBio, has exceeded expectations. Q4 2025 sales reached \$343 million, reflecting >13% growth and a \$1.4 billion annualized run rate. AnaptysBio received a one-time \$75 million commercial sales milestone from GSK after Jemperli surpassed \$1 billion in worldwide net sales in November 2025.

AnaptysBio expects to achieve >\$390 million in annualized Jemperli royalties at GSK’s peak sales guidance of over \$2.7 billion, possibly as early as 2029. These future royalty streams are a core asset and could be highly price-sensitive, especially as GSK continues to invest in expanding Jemperli’s indications, including pivotal Phase 2 and 3 trials in rectal and colon cancer, and head and neck cancer.

The company estimates that Sagard, which previously provided non-recourse debt monetization, will have accrued ~\$250 million in royalties and sales milestones through year-end 2025, with the full paydown of \$600 million by Q2 2027.

Pipeline Progress and Upcoming Catalysts

• ANB033 (CD122 Antagonist):
  • Phase 1b trial in celiac disease is ongoing (60 patients, two cohorts: gluten-challenge and mucosal healing studies). Top-line data for both cohorts is anticipated in Q4 2026.
  • Phase 1b trial in eosinophilic esophagitis (50-patient cohort) initiated in Q1 2026, with top-line data expected in 2027.
• Rosnilimab (Pathogenic T Cell Depleter):
  • Phase 2b data for rheumatoid arthritis presented at ACR 2025. Future development contingent on strategic or external funding, with updates expected in Q2 2026.
• ANB101 (BDCA2 Modulator):
  • Phase 1a trial in healthy volunteers ongoing. Early data suggests superior potency and durability compared to Biogen’s litifilimab.
• Imsidolimab (IL-36R Antagonist):
  • FDA accepted the BLA for generalized pustular psoriasis in February 2026; target action date December 12, 2026. License agreement with Vanda Pharmaceuticals could provide additional milestones and royalties.

Financial Update: Strong Balance Sheet and Shareholder Returns

• Cash, cash equivalents, and investments totaled \$311.6 million as of December 31, 2025, down from \$420.8 million in 2024. The decrease primarily reflects \$130.6 million used for operations and \$68.6 million for share repurchases, offset by \$75.0 million from GSK and \$15.0 million from Vanda.
• Collaboration revenue rose sharply to \$234.6 million for 2025, compared to \$91.3 million in 2024, driven by Jemperli milestones and royalties and Vanda licensing revenue.
• Research and development expenses declined to \$136.0 million in 2025 (from \$163.8 million in 2024) due to lower costs on legacy programs, though offset by increased investment in ANB033 and ANB101.
• Net income for Q4 2025 was \$49.6 million (or \$1.79 per share basic, \$1.58 diluted), with a full-year net loss of \$13.2 million (\$0.46 per share), a marked improvement over the prior year’s \$145.2 million loss (\$5.12 per share).
• The company repurchased 3,444,079 shares (11.2% of shares outstanding) in 2025 under its \$175 million stock repurchase program, demonstrating commitment to shareholder returns and potentially supporting the share price.

Leadership and Governance

The spin-off will be led by CEO Daniel Faga, with a board comprised of well-known industry figures, including Dennis Fenton, Ph.D., John Orwin (Chairman), John Schmid, Mark Marquet, Ph.D., Rita Jain, M.D., and Tony Ware, M.D. This leadership continuity and experience may reassure investors about execution and strategic focus during the transition.

Outlook and Potential Share Price Drivers

• The pending separation of the biopharma business may unlock hidden value by letting investors focus on either the royalty/financial asset profile or the innovative pipeline development, each with distinct risk-reward profiles.
• Jemperli’s continued sales momentum and future milestone/royalty payments represent a material source of non-dilutive cash flow and could be highly price sensitive, especially if GSK’s peak sales guidance is achieved or exceeded.
• Upcoming top-line clinical data (ANB033, rosnilimab, ANB101) and regulatory milestones (imsidolimab BLA) are important catalysts that may impact valuation as they approach in late 2026 and 2027.
• The substantial cash position and share buybacks demonstrate strong balance sheet discipline and commitment to shareholder value.

Conclusion

The 2025 results and strategic updates from AnaptysBio are highly significant for investors. The planned spin-off, strong cash position, ongoing royalty streams, and advancing pipeline set up multiple near-term and long-term catalysts that could impact the share price. Investors should closely monitor regulatory, clinical, and financial milestones throughout 2026 and beyond.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making investment decisions. Forward-looking statements are subject to risks as disclosed by the company.

View ANAPTYSBIO, INC Historical chart here